Un estudio para evaluar TAR-210 frente al tratamiento del cáncer intravesical con agente único en participantes con cáncer de vejiga (MoonRISe-1)
Un estudio aleatorizado de fase 3 que evalúa la eficacia y seguridad del sistema de administración intravesical de erdafitinib TAR-210 frente a la quimioterapia intravesical de agente único en participantes con cáncer de vejiga no invasivo muscular (IR-NMIBC) de riesgo intermedio y alteraciones susceptibles del FGFR
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Study Contact
- Número de teléfono: 844-434-4210
- Correo electrónico: Participate-In-This-Study1@its.jnj.com
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- Activo, no reclutando
- Charite - Universitaetsmedizin Berlin (CCM)
-
Braunschweig, Alemania, 38126
- Reclutamiento
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Cologne, Alemania, 50968
- Reclutamiento
- Studienzentrum Bayenthal
-
Dresden, Alemania, 01307
- Terminado
- Urologische Gemeinschaftspraxis
-
Frankfurt am Main, Alemania, 60596
- Reclutamiento
- Universitaetsklinikum Frankfurt
-
Hamburg, Alemania, 22081
- Activo, no reclutando
- Urologikum Hamburg MVZ - Germany
-
Herne, Alemania, 44625
- Reclutamiento
- Marien hospital Herne
-
Jena, Alemania, 07747
- Activo, no reclutando
- Universitatsklinikum Jena
-
München, Alemania, 81675
- Terminado
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Straubing, Alemania, 94315
- Reclutamiento
- Klinikum St. Elisabeth Straubing GmbH
-
Stuttgart, Alemania, 70174
- Terminado
- Katharinenhospital Innere Medizin
-
-
-
-
-
Buenos Aires, Argentina, C1419AHN
- Activo, no reclutando
- Hospital Sirio Libanes
-
Chabas, Argentina, C1425
- Activo, no reclutando
- Investigaciones Clinico Moleculares (ICM)
-
Córdoba, Argentina, 5000
- Activo, no reclutando
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba, Argentina, X5000KPH
- Activo, no reclutando
- Centro Urologico Profesor Bengio
-
Mar del Plata, Argentina, B7602
- Activo, no reclutando
- Hospital Privado de la Comunidad
-
Rosario, Argentina, 2000
- Activo, no reclutando
- Sanatorio de la Mujer
-
-
-
-
-
Graz, Austria, 8036
- Reclutamiento
- Medizinische Universitaet Graz
-
Innsbruck, Austria, 6020
- Reclutamiento
- Medizinische Universitat Innsbruck
-
Leopoldsdorf (Wien), Austria, 1090
- Reclutamiento
- Medical University Vienna MUV
-
Linz, Austria, 4020
- Reclutamiento
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg, Austria, 5020
- Reclutamiento
- Universitaetsklinikum Salzburg Landeskrankenhaus
-
-
-
-
-
Barretos, Brasil, 14780-070
- Activo, no reclutando
- Fundacao Pio XII
-
Campinas, Brasil, 13083-888
- Terminado
- Universidade Estadual De Campinas
-
Natal, Brasil, 59062 000
- Activo, no reclutando
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasil, 90035-001
- Activo, no reclutando
- Hospital Moinhos de Vento
-
Porto Alegre, Brasil, 90050 170
- Activo, no reclutando
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Salvador, Brasil, 41810-011
- Activo, no reclutando
- HBA SA Assitencia Medica e Hospitalar
-
Santo André, Brasil, 09060-650
- Activo, no reclutando
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasil, 01246-000
- Activo, no reclutando
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brasil, 01509 900
- Terminado
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasil, 01221-020
- Activo, no reclutando
- Irmandade Santa Casa de Misericordia de Sao Paulo
-
São Paulo, Brasil, 01323 900
- Activo, no reclutando
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Aalst, Bélgica, 9300
- Reclutamiento
- AZORG campus Aalst Moorselbaan
-
Brugge (Bruges), Bélgica, 8000
- Reclutamiento
- AZ Sint-Jan
-
Edegem, Bélgica, 2650
- Terminado
- UZ Antwerpen
-
Gent (Ghent), Bélgica, 9000
- Reclutamiento
- AZ Maria Middelares
-
Leuven, Bélgica, 3000
- Activo, no reclutando
- Universitair Ziekenhuis Gasthuisberg
-
Sint-Niklaas, Bélgica, 9100
- Reclutamiento
- Vitaz
-
Yvoir, Bélgica, 5530
- Reclutamiento
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Hradec Králové, Chequia, 500 05
- Terminado
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Chequia, 779 00
- Reclutamiento
- Fakultni nemocnice Olomouc
-
Prague, Chequia, 128 08
- Reclutamiento
- Vseobecna fakultni nemocnice v Praze
-
Prague, Chequia, 150 06
- Reclutamiento
- Fakultni nemocnice v Motole
-
Prague, Chequia, 140 59
- Reclutamiento
- Fakultni Thomayerova nemocnice
-
-
-
-
-
Chuncheon, Corea del Sur, 28644
- Terminado
- Chungbuk National University Hospital
-
Gyeongin, Corea del Sur, 10408
- Reclutamiento
- National Cancer Center
-
Sangam-dong, Corea del Sur, 58128
- Reclutamiento
- Chonnam National University Hwasun Hospital
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Samsung Medical Center
-
Seoul, Corea del Sur, 3080
- Reclutamiento
- Seoul National University Hospital
-
Seoul, Corea del Sur, 06591
- Activo, no reclutando
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Aarhus, Dinamarca, 8200
- Reclutamiento
- Aarhus University Hospital
-
Copenhagen, Dinamarca, 2100
- Reclutamiento
- Rigshospitalet
-
Herlev, Dinamarca, 2730
- Reclutamiento
- Herlev Hospital
-
Odense, Dinamarca, 5000
- Reclutamiento
- Odense Universitetshospital
-
Roskilde, Dinamarca, 4000
- Reclutamiento
- Zealand University Hospital
-
-
-
-
-
Alzira, España, 46600
- Reclutamiento
- Hosp. Univ. de La Ribera
-
Barcelona, España, 08025
- Reclutamiento
- Fund. Puigvert
-
Barcelona, España, 08036
- Reclutamiento
- Hosp Clinic de Barcelona
-
Barcelona, España, 08035
- Terminado
- Hosp Univ Vall D Hebron
-
Cadiz, España, 11009
- Reclutamiento
- Hosp. Puerta Del Mar
-
Castillón, España, 12004
- Reclutamiento
- Hosp. Gral. Univ. de Castellon
-
Jerez de la Frontera, España, 11407
- Reclutamiento
- Hosp. de Jerez de La Frontera
-
La Coruña (A Coruña), España, 15006
- Reclutamiento
- Hosp Univ A Coruna
-
Madrid, España, 28041
- Reclutamiento
- Hosp. Univ. 12 de Octubre
-
Madrid, España, 28027
- Reclutamiento
- Clinica Univ. de Navarra
-
Madrid, España, 28007
- Terminado
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga, España, 29010
- Reclutamiento
- Hosp Virgen de La Victoria
-
Oviedo, España, 33011
- Terminado
- Hosp. Univ. Central de Asturias
-
Sabadell, España, 08208
- Reclutamiento
- Hosp.Univ.Parc Tauli
-
Seville, España, 41013
- Terminado
- Hosp. Virgen Del Rocio
-
Valencia, España, 46010
- Reclutamiento
- Hosp. Clinico Univ. de Valencia
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72211
- Terminado
- Arkansas Urology
-
-
California
-
Los Alamitos, California, Estados Unidos, 90720
- Activo, no reclutando
- Genesis Research LLC
-
Los Angeles, California, Estados Unidos, 90033
- Activo, no reclutando
- USC Norris Comprehensive Cancer Center
-
Orange, California, Estados Unidos, 92868
- Activo, no reclutando
- University of California Irvine Medical Center
-
San Diego, California, Estados Unidos, 92123
- Activo, no reclutando
- Om Research LLC
-
Sherman Oaks, California, Estados Unidos, 91411
- Terminado
- Genesis Research LLC 1
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Terminado
- University of Colorado Cancer Center Anschultz Cancer Pavilion
-
Lakewood, Colorado, Estados Unidos, 80228
- Activo, no reclutando
- Colorado Clinical Research
-
San Luis, Colorado, Estados Unidos, 63141
- Terminado
- Mercy Research
-
San Luis, Colorado, Estados Unidos, 63141
- Activo, no reclutando
- Specialty Clinical Research of St Louis
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Activo, no reclutando
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Terminado
- Northwestern University
-
-
Indiana
-
Jeffersonville, Indiana, Estados Unidos, 47130
- Terminado
- First Urology
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67226
- Activo, no reclutando
- Wichita Urology Group
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121-2429
- Activo, no reclutando
- Ochsner Health System
-
-
Maryland
-
Hanover, Maryland, Estados Unidos, 21076
- Terminado
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Terminado
- Brigham And Women's Hospital
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Activo, no reclutando
- Karmanos Cancer Institute
-
Royal Oak, Michigan, Estados Unidos, 48073
- Activo, no reclutando
- Comprehensive Urology
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68114
- Activo, no reclutando
- The Urology Center, PC
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Activo, no reclutando
- Cancer Institute Of New Jersey
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Activo, no reclutando
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Estados Unidos, 10016
- Terminado
- Integrated Medical Professionals
-
Syracuse, New York, Estados Unidos, 13210
- Activo, no reclutando
- SUNY Upstate Med Univ
-
Syracuse, New York, Estados Unidos, 13210
- Activo, no reclutando
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Activo, no reclutando
- Levine Cancer Institute
-
Raleigh, North Carolina, Estados Unidos, 27612
- Activo, no reclutando
- Associated Urologists of North Carolina
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Estados Unidos, 19004
- Terminado
- MidLantic Urology
-
Lancaster, Pennsylvania, Estados Unidos, 17604
- Activo, no reclutando
- Keystone Urology Specialists
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Activo, no reclutando
- Carolina Urologic Research Center
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Activo, no reclutando
- The Conrad Pearson Clinic
-
Knoxville, Tennessee, Estados Unidos, 37920
- Terminado
- University of Tennessee Medical Center
-
Nashville, Tennessee, Estados Unidos, 37209
- Activo, no reclutando
- Urology Associates
-
-
Texas
-
Austin, Texas, Estados Unidos, 78745
- Activo, no reclutando
- Urology Austin
-
Dallas, Texas, Estados Unidos, 75231
- Activo, no reclutando
- Urology Clinics of North Texas
-
Dallas, Texas, Estados Unidos, 75390
- Terminado
- UT Southwestern
-
Houston, Texas, Estados Unidos, 77027
- Activo, no reclutando
- Houston Metro Urology
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99202
- Activo, no reclutando
- Spokane Urology
-
-
-
-
-
Lille, Francia, 59000
- Terminado
- Hospital Center University De Lille
-
Limoges, Francia, 87000
- Reclutamiento
- Polyclinique de Limoges - Francois Chenieux
-
Lyon, Francia, 69003
- Reclutamiento
- Hôpital Edouard Herriot
-
Marseille, Francia, 13009
- Reclutamiento
- Institut Paoli Calmettes
-
Paris, Francia, 75010
- Reclutamiento
- Hopital Saint Louis
-
Paris, Francia, 75013
- Reclutamiento
- CHU Pitie Salpetriere
-
Paris, Francia, 75018
- Reclutamiento
- APHP - Hopital Bichat - Claude Bernard
-
Quint-Fonsegrives, Francia, 31130
- Reclutamiento
- Clinique de la Croix du Sud
-
Rennes, Francia, 35000
- Terminado
- Chu Rennes Hopital Pontchaillou
-
Toulouse, Francia, 31059
- Reclutamiento
- CHU Rangueil
-
Villejuif, Francia, 94805
- Reclutamiento
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hong Kong
- Activo, no reclutando
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Activo, no reclutando
- Prince Of Wales Hospital
-
-
-
-
-
Cork, Irlanda, T12 DC4A
- Activo, no reclutando
- Cork University Hospital
-
Dublin, Irlanda, D07 A8NN
- Activo, no reclutando
- Mater Misericordiae University Hospital
-
Dublin, Irlanda, D07 WKW8
- Activo, no reclutando
- Mater Private Hospital
-
Dublin, Irlanda, D24 NR0A
- Activo, no reclutando
- Adelaide and Meath Hospital
-
-
-
-
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Health Care Campus
-
Ramat Gan, Israel, 52621
- Reclutamiento
- Sheba Medical Center
-
Sderot, Israel, 13100
- Reclutamiento
- Ziv Medical Center
-
Tel Aviv, Israel, 6423906
- Reclutamiento
- Sourasky Medical Center
-
Yeruham, Israel, 9112001
- Terminado
- Hadassah University Hospita Ein Kerem
-
-
-
-
-
Arezzo, Italia, 52100
- Reclutamiento
- Ospedale S. Donato Arezzo, USL 8 - U.O. Oncologia Medica
-
Bergamo, Italia, 24125
- Reclutamiento
- Cliniche Humanitas Gavazzeni
-
Brescia, Italia, 25123
- Reclutamiento
- ASST Spedali Civili Brescia
-
Milan, Italia, 20133
- Reclutamiento
- Istituto Dei Tumori Di Milano
-
Milan, Italia, 20132
- Terminado
- Ospedale San Raffaele
-
Romagnano, Italia, 00128
- Reclutamiento
- Universita Campus Bio-Medico di Roma
-
Romagnano, Italia, 00144
- Reclutamiento
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Italia, 20089
- Reclutamiento
- Istituto Clinico Humanitas
-
Torino, Italia, 10126
- Reclutamiento
- A.O.Citta della Salute e della Scienza di Torino
-
-
-
-
-
Amagasaki, Japón, 660 8550
- Activo, no reclutando
- Hyogo Prefectural Amagasaki General Medical Center
-
Kawasaki, Japón, 216 8511
- Reclutamiento
- St Marianna University Hospital
-
Kobe, Japón, 650 0047
- Activo, no reclutando
- Kobe City Medical Center General Hospital
-
Kumamoto, Japón, 860 0008
- Activo, no reclutando
- National Hospital Organization Kumamoto Medical Center
-
Osaka, Japón, 541 8567
- Reclutamiento
- Osaka International Cancer Institute
-
Saitama, Japón, 350 8550
- Activo, no reclutando
- Saitama Medical Center
-
Wakayama, Japón, 640 8558
- Activo, no reclutando
- JRC Wakayama Medical Center
-
Yokohama, Japón, 221 0855
- Reclutamiento
- Yokohama Municipal Citizen's Hospital
-
Yokohama, Japón, 232 0024
- Activo, no reclutando
- Yokohama City University Medical Center
-
Yokosuka, Japón, 238 8558
- Reclutamiento
- Yokosuka Kyosai Hospital
-
Ōta-ku, Japón
- Reclutamiento
- Gunma Prefectural Cancer Center
-
-
-
-
-
Bialystok, Polonia, 15 276
- Activo, no reclutando
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polonia, 85 048
- Activo, no reclutando
- IN VIVO Sp. z o.o
-
Bydgoszcz, Polonia, 85 796
- Terminado
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Lublin, Polonia, 20 090
- Activo, no reclutando
- Uniwersytecki Szpital Kliniczny nr 4
-
Przemyśl, Polonia, 37 700
- Activo, no reclutando
- Wojewodzki Szpital im Sw Ojca Pio w Przemyslu
-
Tarnów, Polonia, 33-100
- Activo, no reclutando
- Szpital Wojewodzki Im Sw Lukasza Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Tarnowie
-
Torun, Polonia, 87-100
- Terminado
- Medicover Integrated Clinical Services Sp z o o
-
Wiele, Polonia, 05-135
- Activo, no reclutando
- Mazowiecki Szpital Onkologiczny Sp z o o
-
Wroclaw, Polonia, 50 981
- Terminado
- 4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
-
Wroclaw, Polonia, 53-413
- Activo, no reclutando
- Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii
-
-
-
-
-
Beijing, Porcelana, 100191
- Activo, no reclutando
- Peking University Third Hospital
-
Beijing, Porcelana, 100050
- Activo, no reclutando
- Beijing Friendship Hospital Capital Medical University
-
Changsha, Porcelana, 410013
- Activo, no reclutando
- Hunan Cancer hospital
-
Chengdu, Porcelana, 610041
- Activo, no reclutando
- West China School of Medicine/West China Hospital, Sichuan University
-
Chengdu, Porcelana, 610014
- Activo, no reclutando
- The Third People's Hospital of Chengdu
-
Chongqing, Porcelana, 400033
- Activo, no reclutando
- Chongqing Cancer Hospital
-
Fuzhou, Porcelana, 350001
- Activo, no reclutando
- Fujian Medical University Union Hospital
-
Guangzhou, Porcelana, 510060
- Activo, no reclutando
- Sun Yat Sen University Cancer Center
-
Nanjing, Porcelana, 210008
- Activo, no reclutando
- Nanjing Drum Tower Hospital
-
Nanjing, Porcelana, 210009
- Activo, no reclutando
- Zhongda Hospital Southeast University
-
Shanghai, Porcelana, 200031
- Activo, no reclutando
- Huadong Hospital Affiliated to Fudan University
-
Tianjin, Porcelana, 300061
- Activo, no reclutando
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Porcelana, 325000
- Activo, no reclutando
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Porcelana, 430032
- Activo, no reclutando
- Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Xinshi, Porcelana, 710063
- Activo, no reclutando
- The First Affiliated Hospital of Xian Jiaotong University
-
Xuzhou, Porcelana, 221004
- Activo, no reclutando
- The Affiliated Hospital of Xuzhou Medical University
-
Ürümqi, Porcelana, 830011
- Activo, no reclutando
- Cancer Hospital of Xinjiang Medical University
-
-
-
-
-
Bristol, Reino Unido, BS105NB
- Activo, no reclutando
- Southmead Hospital
-
London, Reino Unido, W6 8RF
- Activo, no reclutando
- Charing Cross Hospital
-
London, Reino Unido, EC1A 7BE
- Activo, no reclutando
- St Bartholomews Hospital
-
Newcastle upon Tyne, Reino Unido, NE7 7DN
- Activo, no reclutando
- Newcastle Freeman Hospital
-
Sheffield, Reino Unido, S10 2SJ
- Activo, no reclutando
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Southampton, Reino Unido, SO16 6YD
- Activo, no reclutando
- Southampton General Hospital
-
Sutton, Reino Unido, SM2 5PT
- Activo, no reclutando
- Royal Marsden Hospital
-
-
-
-
-
?zmir, Turquía (Türkiye), 35330
- Reclutamiento
- Dokuz Eylul University Medical Faculty
-
Adana, Turquía (Türkiye), 01120
- Terminado
- Adana Baskent Practice and Research Hospital
-
Ankara, Turquía (Türkiye), 06200
- Reclutamiento
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turquía (Türkiye), 06100
- Terminado
- Ankara University Medical Faculty
-
Istanbul, Turquía (Türkiye), 34722
- Reclutamiento
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul, Turquía (Türkiye), 34153
- Terminado
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul, Turquía (Türkiye), 34865
- Reclutamiento
- Kartal Dr Lutfi Kirdar sehir Hastanesi
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Main study only: Have a histologically confirmed diagnosis (within 90 days of randomization) of IR-NMIBC with at least one of the following criteria fulfilled: a. Ta low grade (LG)/ Grade 1 (G1): primary or recurrent, b. Ta LG/G2: primary or recurrent and c. Greater than or equal to (>=) 1 of the following risk factors: i. Multiple Ta LG tumors, ii. Solitary LG tumor >= 3 cm, iii. Early recurrence (less than [<] 1 year), iv. Frequent recurrence (greater than [>] 1 per year), v. Recurrence after prior adjuvant intravesical treatment (single perioperative dose of chemotherapy does not fulfill this risk factor)
- Substudy only: Have a histologically confirmed new diagnosis (within 90 days of randomization) of IR-NMIBC for whom MMC is deemed the therapy of choice according to local standard of care with at least 1 of the following criteria fulfilled: a. Ta LG/G1, b. Ta LG/G2, and >=1 of the following risk factors: i) Multiple Ta LG tumors, ii) Solitary LG tumor >=3 cm
- Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing
- Participants must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for assessment of recurrence/progression) and receive the assigned treatment, including intravesical chemotherapy if randomized into that arm.
- Visible papillary disease must be fully resected prior to randomization and absence of disease must be documented at Screening cystoscopy
- Can have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Have an Eastern Cooperative Oncology Group performance status of 0 to 2
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to any study component or its excipients, including: a. Erdafitinib excipients; b.TAR-210 drug delivery system constituent materials ; c. urinary placement catheter materials; d. MMC or chemically related drugs; e. Gemcitabine or chemically related drugs
- Presence of any bladder or urethral anatomic feature (that is, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-210 or passage of a urethral catheter for intravesical chemotherapy
- Polyuria with recorded 24-hour urine volumes > 4000 milliliters (mL)
- Current indwelling urinary catheters, however, intermittent catheterization is acceptable
- Had major surgery or had significant traumatic injury and/or not fully recovered within 4 weeks before first dose (TURBT is not considered major surgery)
Substudy:
- Previous diagnosis of histologically confirmed urothelial bladder carcinoma at any time prior to current qualifying diagnosis
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Main Study: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Otros nombres:
|
|
Comparador activo: Main Study: Group B: MMC or Gemcitabine
Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
Gemcitabine will be administered intravesically. MMC will be administered intravesically. |
|
Experimental: Substudy: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Otros nombres:
|
|
Comparador activo: Substudy: Group B: MMC
Participants in substudy Group B will receive intravesical MMC once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
MMC will be administered intravesically. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease Free Survival (DFS)
Periodo de tiempo: From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
DFS is measured as the time from randomization to the date of the first documented recurrence of Ta non-muscle invasive bladder cancer (NMIBC) of any grade, disease progression, or death due to any cause, whichever occurs first. |
From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to next Treatment (TTNT)
Periodo de tiempo: From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
TTNT is measured as the time from randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer. |
From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
|
High Grade Recurrence-free Survival (HG RFS)
Periodo de tiempo: From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
HG RFS is measured as the time from randomization to the date of first documented evidence of HG NMIBC or death, whichever occurs first |
From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
|
Progression Free Survival (PFS)
Periodo de tiempo: From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
PFS is measured as the time from randomization to the date of first documented evidence of disease progression or death, whichever occurs first. |
From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
|
Number of Diagnostic and Therapeutic Invasive Urological Interventions after Study Treatment
Periodo de tiempo: From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
Number of diagnostic and therapeutic invasive urological interventions after study treatment, that is, endoscopic procedures (e.g., cystoscopies, transurethral resection of bladder tumors (TURBTs), ureteroscopies, urethral interventions, urethral stricture/bladder neck incision), catheterization (intravesical, suprapubic), intravesical treatments, major surgeries (e.g., radical cystectomy, simple cystectomy, urethroplasty) will be reported. |
From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
|
Number of Participants With Adverse Events (Including Physical Examination, Vital Signs and Laboratory Abnormalities)
Periodo de tiempo: From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
An AE is any untoward medical occurrence in a participant participating in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product, that does not necessarily have a causal relationship with the treatment. AEs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening and Grade 5: Death. Number of participants with adverse events (including physical examination, vital signs and laboratory abnormalities) will be reported. |
From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
|
Overall Survival (OS)
Periodo de tiempo: From randomization to the date of death (approximately 4 years and 2 months)
|
OS is defined as the time from randomization to the date of death from any cause. |
From randomization to the date of death (approximately 4 years and 2 months)
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores
Periodo de tiempo: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores
Periodo de tiempo: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-C30 Scores
Periodo de tiempo: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the HRQoL of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-NMIBC24 Scores
Periodo de tiempo: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Neoplasias Urológicas
- Carcinoma
- Enfermedades de la vejiga urinaria
- Neoplasias de la vejiga urinaria
- Neoplasias vesicales sin invasión muscular
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Desoxicitidina
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Gemcitabina
- erdafitinib
Otros números de identificación del estudio
Otros números de identificación del estudio
- 42756493BLC3004
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .